Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer

The introduction of enzalutamide and abiraterone has led to improvement in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, acquired resistance to enzalutamide and abiraterone therapies frequently develops within a short period in many patients. In the present study...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Res
Main Authors: Liu, Chengfei, Lou, Wei, Zhu, Yezi, Yang, Joy C., Nadiminty, Nagalakshmi, Gaikwad, Nilesh W., Evans, Christopher P., Gao, Allen C.
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4383695/
https://ncbi.nlm.nih.gov/pubmed/25649766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-3080
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker